Cxbladder for hematuria evaluation
Cxbladder tests are optimized for the risk stratification of urothelial cancer in patients presenting with hematuria and help de-intensify clinical work-up in patients with a low probability Cxbladder test result. This reduces the need for referral and invasive procedures, while helping to prioritize those that require immediate care.
Effectiveness of cystoscopy. US data highlights the challenge
The need
Each year approximately 7 million US patients present with hematuria and about 2 million are referred to urology for evaluation. 75% of these patients present with microhematuria.
The challenge
While hematuria is the most common symptom of urothelial cancer (UC), the incidence of UC is low in those presenting with symptoms – 3% of patients presenting with microhematuria and 10-25% of those presenting with gross hematuria.
The solution
97% of patients presenting with microhematuria and up to 90% presenting with gross hematuria do not have UC. 70-80% of all cystoscopies linked to hematuria evaluation can be safely avoided using a non-invasive Cxbladder test.
Genomic testing designed to optimize practice workflow
Cxbladder Triage Plus
Cxbladder Triage Plus is a next generation Cxbladder test that employs a novel combination of mRNA and DNA biomarkers to extend best in class performance.
Triage Plus enhances risk stratification, reducing unnecessary cystoscopies in patients with a low probability of UC, while prioritizing those who need immediate care.
With analytical and clinical validation shown in published studies*, Triage Plus builds on the performance of Cxbladder Triage, a test now included in the AUA/SUFU Microhematuria Guideline**, supported with "Grade A" evidence from the STRATA randomized controlled trial.***
Cxbladder Detect
Cxbladder Detect is an established Cxbladder test, optimized for the risk stratification of patients presenting with hematuria. Detect helps to de-intensify clinical work-up in in those with a low probability Detect test result, improving practice workflow and efficiency in urological care, while giving patients the best experience possible.
Featured resource
DRIVE Study validates diagnostic performance of Cxbladder Triage Plus
Leading industry platform Urology Times reviews the DRIVE study, now published in Urologic Oncology. DRIVE provides clinical validation for our next generation Cxbladder test Triage Plus. Cxbladder Triage Plus employs a novel combination of mRNA and RNA biomarkers to extend best in class performance, enhancing the risk stratification of patients presenting with hematuria.
Start your Cxbladder journey
Contact our customer service team
Learn more about the Cxbladder suite and how to implement it in your practice.
Cxbladdder Triage Plus
A test with added DNA markers to better risk stratify hematuria patients
Delivers significant improvement in NPV, Sensitivity, PPV and Specificity over our original Cxbladder Triage test.
Increases the rate of UC rule out in patients with a low probability of disease, deferring those that who do not stand to benefit from an invasive cystoscopy.
Enables the identification and prioritization of high-risk patients with high specificity and PPV (98% specificity and 75% PPV when higher 0.54 cut point on test report is used).
Simplifies practice workflow as a single test optimized for the evaluation of both gross and microhematuria.
Requires a urine sample only. No additional patient factors are required.
Featured resources
The Role of Urine-based Biomarkers in Microhematuria Evaluation
In a recent interview with Urology Times, Dr. John Sfakianos discusses the significance of urine-based biomarkers for intermediate-risk patients and outlines key findings from the STRATA randomized controlled trial.
Advancing Microhematuria Evaluation: The Impact of Urinary Biomarkers and Updated Guidelines
Dr. Jay Raman and Dr. Yair Lotan sit down with Dr. Zachary Klaassen to discuss the latest developments in microhematuria evaluation. Topics include the unmet need in risk stratifying patients, the evolution of the AUA/SUFU Microhematuria Guideline from 2020 to 2025, and the role of urinary biomarkers in optimizing patient care, including Cxbladder Triage, a test now included in the Guideline**.
Real-World Implementation of Biomarkers for Microhematuria Workup
Kaiser Permanente's Dr. Ronald Loo and Dr. Christopher Filson join Dr. Zachary Klaassen to discuss the real-world implementation of Cxbladder Triage within the Kaiser Health System for risk stratification, including the results of a published study of over 3,300 patients.
Cxbladder Detect
An established test for the risk stratification of urothelial cancer
Enables reliable risk stratification. Safely de-intensifies clinical workup in patients with a low probability Detect test result, while prioritizing those that require immediate care.
Spares patients with a low probability Detect test result the discomfort, anxiety and risks of an invasive procedure.
A reliable adjunct when other tests and procedures are inconclusive. Resolves atypical cytology and equivocal cystoscopy.
Optimize your clinical practice while improving the patient experience
The Cxbladder suite helps you prioritize your time and clinical resources on those that need it the most, streamlining practice workflow and increasing overall efficiency.
Cxbladder works for both you and the patient. Spare patients with a low probability of urothelial cancer the discomfort, anxiety and risks of an invasive procedure. With urine-based sampling and the option of in-home sample collection, the Cxbladder suite allows you to optimize your clinical practice while delivering the best patient experience possible.
Cxbladder is a precision test that delivers exceptional performance and clinically actionable results
Cxbladder is an objective test with high sensitivity and NPV.
The Cxbladder suite is supported by an evidence portfolio that includes over 30 peer reviewed publications in leading medical journals.
Cxbladder Triage is now included in the AUA/SUFU Microhematuria Guideline with supporting "Grade A" Evidence**.
The Cxbladder suite of tests have been used by over 5,000 urologists in more than 100,000 patients.
How Cxbladder works
The sampling process
Cxbladder's non-invasive urine sampling system is easy for patients to use, streamlining deployment in-clinic.
The science
Cxbladder is an objective test with high sensitivity and NPV that delivers exceptional performance and clinically actionable results. The test works at a molecular level, analyzing biomarker genes to help risk stratify urothelial cancer.
The test report
The Cxbladder test report have been developed in consultation with leading urologists and provides the patient’s Cxbladder score, alongside an interpretation of the results and an assay description.
The Cxbladder test report
The Cxbladder test report have been developed in consultation with leading urologists and provides the patient’s Cxbladder score, alongside an interpretation of the results and an assay description.
Start your Cxbladder journey
Contact our customer service team
Learn more about the Cxbladder suite and how to implement it in your practice.
Adopting Cxbladder in your clinic
Implementing Cxbladder
Our team are ready to guide and support you in the deployment and use of Cxbladder. Learn more implementation.
Start your Cxbladder journey
Contact our customer service team to learn more about the Cxbladder suite and how to implement it in your practice.
Cxbladder is available around the world
Cxbladder is available in the United States, and in countries across Asia and South America. Cxbladder is also available in New Zealand, Australia, and Israel.
References
* Harvey et al. (2025) Analytical Validation of the Cxbladder® Triage Plus Assay for Risk Stratification of Hematuria Patients for Urothelial Carcinoma. Diagnostics. 2025; 15(14):1739. https://doi.org/10.3390/diagnostics15141739.
* Savage et al. (2025) Diagnostic performance of Cxbladder Triage Plus for the identification and stratification of patients at risk for urothelial carcinoma: The multicenter, prospective, observational DRIVE study. Urologic oncology, S1078-1439(25)00405-3. Advance online publication. https://doi.org/10.1016/j.urolonc.2025.10.008
** Barocas et al. (2025) Updates to Microhematuria: AUA/SUFU Guideline (2025). The Journal of urology, 213(5), 547–557. https://doi.org/10.1097/JU.0000000000004490.
*** Lotan et al. (2024) A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic Microhematuria Trial. The Journal of Urology Vol 212(1) 41-51.